Transcript Title of presentation - Medicines Transparency

MeTA Jordan
Country Overview
Public Sector
Private Sector
Civil Society
17/07/2015
Medicines Transparency Alliance
1
MeTA Jordan
Dr Taher Abu ElSamen
MeTA Council Chair
HHC Secretary General
17/07/2015
Medicines Transparency Alliance
2
Multi-stakeholder process (1)
The Multi-stakeholder process in Jordan started by:

Establishing the MeTA Council based on a multi-stakeholder
membership , the MeTA Council is represented fully by multistakeholder, public and private sectors and the CSO, and they
all agreed on a national country workplan
17/07/2015
Medicines Transparency Alliance
3
Multi-stakeholder in MeTA Council
HHC
JPD
RMS
JFDA
MOH
Pharmacy
Dept
JUH
MOH
KAUH
Supply &
Procurement
Dpt.
Civil Society
& Patient
groups
Professional
Associations
Private
Sector
Local
Industry
MeTA Int. Partners
7/17/2015
Medicines Transparency Alliance
MeTA
Council
WHO
DFID
Academia
WB
Multi-stakeholder process (2)

MeTA Jordan used the national forum Nov. 2009 as an
opportunity to re-motivate and engage stakeholders especially
the private sector and the CSOs. The diversity of the
represented attendees gave a unique flavor for the forum
especially during the discussion session

The one day multi-stakeholder collaboration for MeTA pilot
countries workshop carried out by Wageningen University in
January 2010 was a success, 70 attendees from all MeTA
Countries attended, since it supported the multi-stakeholder
dialogue and collaboration by encouraging the active
participation of key stakeholders from public, private and CSOs

Conducting the data disclosure survey was an opportunity not
only to collect data but also to work together as a multistakeholder, share information and exchange ideas which
created more interest and commitment for future activities
17/07/2015
Medicines Transparency Alliance
5
Multi-stakeholder process (3)

MeTA Jordan will carry out the stakeholder mapping and
communication audits in July 2010 through the IDS (part of
Component 3 of the MeTA baseline assessment) to help map out
the local communication partners and individual consultants. The
work aims to create ‘communication’ or ‘learning’ spaces where
MeTA representatives have a chance to reflect on their
experiences and share these with a view to encouraging
innovation and change

Having MeTA in Jordan was an opportunity to get key people
working in the pharmaceutical sector engage together in a multistakeholder membership and including patients along the way

MeTA Jordan stakeholders reached a stage that they need skills
to help them communicate with representatives of institutional
partners who may come from very different positions
17/07/2015
Medicines Transparency Alliance
6
Multi-stakeholder process (4)

MeTA Jordan stakeholders are thinking strategically to develop a
clear brand identity for MeTA and to recommend development of
communication tools and messages to support the multistakeholder process

The International MeTA Secretariat offered countries to identify
and communicate the barriers and ensure that the appropriate
guidance and support is mobilised within MeTA to address them
17/07/2015
Medicines Transparency Alliance
7
Multi-stakeholder Milestones

Establishing a multi-stakeholder MeTA Council

MeTA Jordan national forum invited multi-stakeholder Nov. 2009

One day multi-stakeholder collaboration for MeTA pilot countries
workshop in January 2010

Conducting the disclosure survey with stakeholders working
together

The planned stakeholder mapping and communication audits to
take place in July 2010 through the IDS

MeTA Jordan stakeholders have identifies the skills neded to help
them communicate with representatives of institutional partners
who may come from very different positions, planned between
July and Sep. 2010
17/07/2015
Medicines Transparency Alliance
8
Overall challenges in multistakeholder process

A new concept and idea, it needs more time for people to accept
and understand

Lack of experience of multi-stakeholder process and the need for
different communication skills for members

Inter-personal /inter-institutional communication skills for MeTA
Council Members was a challenge, (active listening etc training is
needed)

There are currently issues related to Council members listening
to each other and putting their point across in a nonconfrontational way

People are not all used to operating in a forum where people
represent organizations with such different positions and they
need support on consensus building
17/07/2015
Medicines Transparency Alliance
9
Major achievements and successes
for MeTA in Jordan (1)

The Government is highly supportive of the MeTA process it
supported and hosted MeTA at the HHC, a governmental
institution, this gave the whole process an official identity and
led to have the diverse public sector more engaged

MeTA was launched in Jordan as a high profile national event
in May 09

The highly committed MeTA Council Members started realizing
the concept of transparency, they agreed on a national
workplan based on the NDP, they agreed to publish all
outcomes on Jordan MeTA web site, participated in the data
disclosure survey and issued the first MeTA newsletter on April
2010

Jordan had hosted a session at the WHA on transparency and
good governance May 09
17/07/2015
Medicines Transparency Alliance
10
Major achievements and successes
for MeTA in Jordan (2)

The MeTA process has opened channels of communication
between different stakeholders and between different countries.
Common understanding of each of the other stakeholder
perspectives was identified, the fact that there are common
priorities and one objective between stakeholders became more
clear

MeTA council private sector representative attended the private
sector meeting in London June 09

Pharmaceutical Baseline Assessment Survey-Level II and a
WHO/HAI surveys took place

Supply Chain Mapping assessment took place in March 09

A Successful National Forum Nov 09
17/07/2015
Medicines Transparency Alliance
11
Major achievements and successes
for MeTA in Jordan (3)
In terms of CSO building capacity area:

The CSO committee has drafted a CSO workplan where it is
derived form the three major priorities in the overall national
MeTA workplan in Jordan, “Build capacity of (CSOs) to monitor
and increase accountability of all stakeholders with respect to the
prices, availability, selection and quality of medicines in the public
and private sectors

A nucleus of a CSO coalition has started to form and a MoU was
signed with the Int. MeTA Secretariat in November 2009 and a
specific CSO workplan was approved accordingly the voice of
patient is now becoming heard by the Government policy makers
The very first activity was conducted to map and identify CSOs to
assess their ability and willingness to work together and to
engage them with the MeTA council, this activity has set the
baseline work for the CSOs in Jordan
17/07/2015 Medicines Transparency Alliance
12

Major achievements and successes
for MeTA in Jordan (4)
In terms of CSO building capacity area:

Workshop on building capacity of CSOs in order to
strengthen their ability to monitor and increase accountability
of all stakeholders regarding medicines prices, availability,
selection and quality of medicines

CSOs have Participated in the Harvard Flagship course and
have participated in the country exchange visit to the
Philippines

Conduct a training on advocacy and communications in
improving access to essential medicinesThe CSO level of
engagement with the MeTA process is moving forward
gradually

At the start of the process there was limited activities and
meeting but since November they become more engaged
17/07/2015
Medicines Transparency Alliance
MeTA
13
Major achievements and successes
for MeTA in Jordan (5)
In terms of evidence based medicine:

Reviewed TORs and SOPs of various (therapeutic arearelated) committees involved in selection of drugs to be
included in Rational Drug List (RDL), reviewed criteria for
adding and deleting drugs to and from the RDL, and finally
reviewed classification of drugs (Restricted, Un-Restricted,
Authorized and Un- Authorized) in RDL

Introduce the pharmaco- economics concept and its importance
for RDL addition and deletion to the local industry and generic
importers

A series of training sessions on pharmaco-economics to PTC
17/07/2015
Medicines Transparency Alliance
14
Major achievements and successes
for MeTA in Jordan (6)
In terms of RDU:

NICE has Pilot the development of an evidence-based care
pathway, first step was (STG Gap Analysis in the public sector
and second step was developing essential Hypertension STG)
for all public primary health care facilities

Conducted a Promotional for Rational Drug Use workshop
17/07/2015
Medicines Transparency Alliance
15
Overall Challenges (1)
At Pharmaceutical level:

Poor forecasting and estimation of medicines needs which led to
low availability of medicines in public sector

High Health expenditure 9.05% of GDP where 34% out of it is
spent on medicines with 2/3 expenditure is out of pocket and all
this is seen as our fault and Irrational Use of Medicines

Willingness of the private sector to share information, such as
information related to prices, promotional activities and quality

High pharmaceutical promotion / hard to control even some
patient group's budgets are partially supported by pharmaceutical
companies

No base line data to measure outcomes
17/07/2015
Medicines Transparency Alliance
16
Overall challenges (2)
At the MeTA Level:

Short period, the two year MeTA pilot is not enough to present
and measure the impact on the availability and RDU,, as much as
we worked and contributed as a sector the outcome will be
noticed through years to come

We started the MeTA process with no base line data to rely on,
the base line data to be collected started after the MeTA process
commenced

Changes in MeTA Council representatives positions/agendas can
hinder their participation in medicines policy changes and creates
a gap between Council members

Private sector is poorly represented in the MeTA Council
17/07/2015
Medicines Transparency Alliance
17
Overall challenges (3)

MeTA has acted as a coordinating body for the pharmaceutical
sector, also the MeTA process has opened channels of
communication between different stakeholders and between
different countries

The international and the national MeTA Secretariat coordination
role is integral for the MeTA process to move forward

The Consultants Technical Advisory role is of a high value for the
MeTA process and in improving quality of implementation of the
national workplan

The multi-stakeholders ( public, private and CSOs) process in
very hard, it takes time to have the stakeholders understand each
other's perspectives and identify that there were in fact common
priorities and one objective to work on together
17/07/2015
Medicines Transparency Alliance
18
Overall Challenges (4)
At the MeTA Level:

CSOs are still not represented in drug related committees like the
Pricing Committee or Higher Drug Committee

Difficulty in attracting new CSO groups to join the MeTA CSO
coalition and there is an absence of coordination or sharing of
expertise and experiences among the various CSOs

Limited participation of CSO representatives in MeTA Baseline
Data Disclosure Survey and no coordination for the CSOs work

Poor role of the CSOs in the decision making process with limited
role in patient counseling
17/07/2015
Medicines Transparency Alliance
19
Lessons Learned (1)

To continue exploring national opportunities for pursuing MeTA
post-pilot in Jordan

Looking for sustainability when MeTA ends in the country, we
need to keep searching for other fund and contact other
international partners like EU

Opening channels with media to engage external stakeholders
with the MeTA process and raise public awareness

To recommend activities and present a prioritised workplan to the
International MeTA Secretariat for discussion as soon

MeTA has acted as a coordinating body for people working in the
pharmaceutical sector
17/07/2015
Medicines Transparency Alliance
20
Lessons Learned (2)

CSO engagement with the MeTA process complements the
overall picture and highlights patients’ need. Capacity for CSOs
to engage more effectively needs to be built

A budget for a CSO coordinator should have been listed in the
CSO workplan and there should be an organized structure for the
CSO coalition

To engage parliament in the MeTA council process

The stakeholders started to understand each others perspectives
17/07/2015
Medicines Transparency Alliance
21
Lessons Learned (3)

We have learned the Importance of Data Disclosure, many
outputs we were keen to participate in towards disclosure, we
agreed to publish all outcomes on Jordan MeTA Web site and
learned that we should involve media more

The MeTA process has opened channels of communication
between different stakeholders and between different countries

MeTA has acted as a coordinating body for the pharmaceutical
sector players and stakeholders

The Data Disclosure survey was a useful exercise that improved
communication and sharing/disclosing of information- a core
MeTA principle
17/07/2015
Medicines Transparency Alliance
22
Thank you for Listening

Dr Taher Abu El Samen

Email: [email protected]

Mobile number: +962 79 726 7444

Website: www.meta.jo
17/07/2015
Medicines Transparency Alliance
23
Public Sector
Presenter Name
Job Title
17/07/2015
Medicines Transparency Alliance
24
Overview of Public Health Sector in
Jordan

Jordan is characterized by a diverse and fragmented public
sector. It consists of: MOH, Royal Medical Services, Jordan
University Hospital, King Abdullah the Second University
Hospital, King Husain Cancer Center and Prince Hamzeh
Hospital

The public sector covers about 72% of the population

Pharmaceutical expenditure as a percent of total health expenditure is
34.0%, where public accounts for 11.3%

Public pharmaceutical expenditure as a percentage of total
pharmaceutical expenditure accounts for 33.3%.

Pharmaceutical expenditure is growing at 17% per annum compared to
GDP growth of 3.3%

The public sector is represented at the Jordan MeTA Council by 9
members out of 18
Source: Jordan National Health Accounts (NHA) 2007
17/07/2015
Medicines Transparency Alliance
MeTA
25
Comparison of Jordan Public Expenditure
on Medicines with other Countries
Norway
DEVELOPED COUNTRIES (7-23)
Denmark
France
Germany
Greec
Lithuania
TRABSITIONA COUNTRIES (15-30)
Slovenia
Crotia
Czech Rep
Bulgaria
South Africa
Argentina
DEVELOPING
DEVELOPED
COUNTRIES
COUNTRIES
(24-66)
(7-20)
Jordan
Indonesia
Mail
0
10
Medicines Transparency Alliance
20
30
40
50
60
70
26
Level of Public Sector Engagement

The Government/ public sector has supported MeTA since the
start of MeTA

The public sector actively participates in all MeTA activities at the
level of the Council, subcommittees and established task forces
that work on activities in our national workplan

MeTA Council representatives of the Public sector have acted as
facilitators for the Baseline Pharmaceutical Assessment
Household and Health Facility survey level II, as well as the
Pharmaceutical Sector Scan

The Public Sector is fully committed and are the main drivers for
the MeTA process in Jordan
17/07/2015
Medicines Transparency Alliance
MeTA
27
Level of Public Sector Engagement
cont.

MeTA is hosted at one of the public health sector institutions/ the
High Health Council (HHC)

The elected MeTA Chair is the Secretary General of the HHC

Representatives from public sector were nominated to participate
in the household and health facility survey level II technical
committee.

Representative pharmacists from public sector institutions
participated in facility survey data collection

Most of public sector representative at the MeTA Council actively
participated in the baseline data disclosure survey
17/07/2015
Medicines Transparency Alliance
MeTA
28
Summary Analysis at start of MeTA
The needs and issues in the public sector at the start of MeTA
focused on three main areas:

Improving Availability in the public sector through adapting
and using transparent evidence based decision making for the
Rational Drug List (RDL)

Promoting Rational Drug Use through encouraging best
practice and developing STGs

The need for reliable Data to be used in forecasting etc.
especially with the lack of Health IT within the public sector
17/07/2015
Medicines Transparency Alliance
29
Major Milestones

Developed national Standard Treatment Guidelines (STGs) for essential
hypertension for all public primary health care facilities
(Expected Output: implementation of pilot STG after discussing
implementation strategy with MoH)

Reviewed TORs and SOPs of various (therapeutic area-related)
committees involved in selection of drugs to be included in Rational Drug
List (RDL)
(Expected Output: adoption of revised criteria for SOPs and Conflict of
Interest declarations and increased accountability)


Reviewed criteria for adding and deleting drugs to and from RDL
(Expected Output: adoption of revised criteria and increased
transparency in medicines selection processes)
Reviewed classification of drugs (restricted, unrestricted, authorized and
unauthorized) in RDL
(Expected Output: adoption of revised classifications using
transparent evidence based medicine criteria to inform decisions)
17/07/2015
Medicines Transparency Alliance
30
Major Milestones cont.

For reliable data on medicines availability and use they advised
to have the Pharmaceutical Baseline Assessment Survey-Level
II and a WHO/HAI surveys to take place and contributed data to
them

Supported and contributed to a Supply Chain Mapping
Assessment

Promoted a Rational Drug Use workshop amongst public sector
health workers

Advised that a series of training sessions on pharmacoeconomics take place for health professionals -to date two
training sessions have already taken place

Promote good practice and work on the development of conflict
of interest (COI) declaration and management system for all
committees to improve accountability
17/07/2015
Medicines Transparency Alliance
31
Successes

The Government is highly supportive for the MeTA initiative in
Jordan as mentioned earlier

The public sector is committed to MeTA and they believe in the
MeTA main objective and the five core principles

The Government has supported MeTA and hosted the initiative at
one of the governmental institutions -the HHC. This gave the
whole process an official identity and led to the fragmented public
sector working together towards improving availability through
adapting/using evidence based decision making for the Rational
Drug List (RDL) and promoting RDU through encouraging best
practice
17/07/2015
Medicines Transparency Alliance
32
Challenges
At the level of the Pharmaceutical Sector:

Poor forecasting and estimation of medicines needs which leads
to low availability of medicines in public sector

High Health expenditure 9.05% of GDP where 34% out of it is
spent on medicines with 2/3 expenditure is out of pocket

Direct local purchases by institutions (prices of the private sector)
instead of sticking to procuring jointly through JPD

Irrational Use of Medicines and absence of national STGs in
different disease areas

Weak role and capacity of pharmaco- vigilance system

Lack of private sector transparency
17/07/2015
Medicines Transparency Alliance
33
Challenges cont.
General Challenges:

The two year period for MeTA pilot is too short and not long
enough to measure outcomes and impact on the availability of
medicines in the public sector and on Rational Drug Use

Changes in MeTA Council representatives positions/agendas can
hinder their participation in effecting medicines policy changes
and creates a gap between Council members
17/07/2015
Medicines Transparency Alliance
34
Lessons Learned
1. The main lesson learned is the importance of partnership
AND the multi-stakeholder process:

That public sector can be more effective in dealing with issues
within the medicine supply chain in terms of availability,
distribution, RDU when working with the private sector and civil
society organizations (CSO), since the private sector secures the
country with medicines and the CSO speak on behalf of patients’
and consumers’ and their needs

The MeTA process has opened channels of communication
between different stakeholders and between different countries

MeTA has acted as a coordinating and facilitating body for the
pharmaceutical sector players and stakeholders
17/07/2015
Medicines Transparency Alliance
35
Lessons Learned cont.
2. We have learned the Importance of Data and Data
Disclosure

Participated fully in the Pharmaceutical Sector Data Disclosure
Survey

Contributed fully in the Pharmaceutical Baseline Assessment
Survey-Level II: Facility and household and included the Pricing
Survey within the baseline assessment facility survey

Participated in the Pharmaceutical Sector Scan Survey

Agreed to publish all outputs and data on Jordan MeTA Web site
and learned that the media should be more involved

Identified gaps and formulated recommendations for the Jordan
pharmaceutical sector (based on existing pharmaceutical reform
sector studies (WB 2004) and publish on the Jordan MeTA Web
site
17/07/2015
Medicines Transparency Alliance
36
Thank you

Name of presenter:

Job Title:

Email:

Mobile number: +962

Website: www.meta.jo
17/07/2015
Medicines Transparency Alliance
37
Private Sector

Dr Ibrahim Al Abbadi

Scientific Research Documentation Office Director

The University of Jordan
17/07/2015
Medicines Transparency Alliance
38
Overview of Private Health Sector in
Jordan

60 private hospitals and many specialized private clinics

16 High quality local pharmaceutical manufacturing (branded
generics)

Value of Jordan pharmaceutical market (2008) is 350m USD

80% (in value) corresponds to imported medicines

84 medicines’ local agents and around 160 subagents

1829 registered pharmacies
Reference: Jordan National Health Accounts (NHA) 2007 and Jordan Supply Chain Mapping report (2009)
17/07/2015
Medicines Transparency Alliance
MeTA
39
Overview of Private Health Sector in
Jordan Cont.

Chain pharmacies started operating in Jordan since 2001, the
biggest is Pharmacy One with 45 branches

Pharmaceutical expenditure as a percent of total health
expenditure is 34.0% where the private sector accounts for
22.7%

Distribution of pharmaceutical expenditure as a percentage of
total pharmaceutical expenditure where the private accounts for
66.7%
Reference: Jordan National Health Accounts (NHA) 2007 and Jordan Supply Chain Mapping report (2009)
17/07/2015
Medicines Transparency Alliance
40
Jordanian Pharmaceutical Exports
million US $
500
400
300
200
100
0
1999
2001
2003
2005
2007
The Target is 1 billion $ in 2011
17/07/2015
Medicines Transparency Alliance
Source: Jordan Association of Pharmaceutical Manufactures(2010)
MeTA
41
Summary Analysis at start of MeTA
The main issues for the private sector at the start of MeTA were:

To get engaged more in the strategic planning process for the
pharmaceutical sector in our country, and to get engaged more
with the public sector and to share data and information on
availability and patients needs
17/07/2015
Medicines Transparency Alliance
42
Major milestones

The private sector represented by the local industry association
as one of the MeTA council members

The Medical and Pharmacy associations are represented in the
MeTA council

Participated in most of MeTA activities on the level of the council
membership , the level of subcommittees and on the level of
established task forces that are working on activities listed on our
national workplan

The MeTA council representatives of the private sector acted as
facilitators for the baseline pharmaceutical surveys

Encouraged the private sector mapping report to be conducted

To conduct a workshop to promote ethical promotion guidelines
17/07/2015
Medicines Transparency Alliance
43
Major milestones Cont.

Introduce the pharmaco-economics concept and its importance
for RDL addition and deletion to the local industry and generic
importers

An introductory meeting about MeTA and its concept to the
medical associations and professional associations

Contributed in reviewing the criteria for adding and deleting
medicines into the RDL , TORs and SOPs for the RDL
committees, revised the classification criteria of drugs (Restricted,
Un-Restricted & Authority required) listed in the RDL

MeTA Council Private sector representative (local pharmaceutical
industry), attended Private Sector meeting in London June 2009

Agreed with the MeTA Council to publish all outcomes on Jordan
MeTA Web site
17/07/2015
Medicines Transparency Alliance
44
Successes

The private sector is represented by the local pharmaceutical
industry, Jordan Pharmacy Association and Jordan Medical
Association

The private sector participate in regular meetings and in most
activities

The private sector represented by the local industry will
participate in a study about the FTA impact on access to
medicine in Jordan

Were involved in reviewing criteria for adding and deleting drugs
to and from the RDL and the TORs and SOPs of various
(therapeutic area-related) committees involved in selection of
drugs to be included in Rational Drug List (RDL) and the
classification of drugs (Restricted, Un-Restricted, Authorized and
Un- Authorized) in RDL
17/07/2015
Medicines Transparency Alliance
45
Challenges
At Pharmaceutical level:

Poor forecasting and estimation of medicines needs which leads
to low availability of medicines in public sector where this will
reflect on us as a private sector

High Health expenditure 9.05% of GDP where 34% out of it is
spent on medicines with 2/3 expenditure is out of pocket

High prices of some essential medicines since the private sector
is securing the country with medicines
17/07/2015
Medicines Transparency Alliance
46
Challenges Cont.

Private sector is not fully represented in the MeTA Council

Private sector low level of disclosing data and low willingness to
share information, such as information related to prices,
promotional activities and quality

Few patients associations budgets are partially supported by
pharmaceutical companies

High pharmaceutical promotion / hard to control
17/07/2015
Medicines Transparency Alliance
MeTA
47
Challenges Cont.

Short period, the two year MeTA pilot is not enough to present
and measure the impact on medicines availability and RDU, as
much as we worked and contributed as a sector the outcome will
be noticed through years to come

In order to present as a sector that we contributed to the main
issues identified we needed more time to have this contribution
measured by data to be presented to the whole public

Lack of adherence to ethical promotion guidelines
17/07/2015
Medicines Transparency Alliance
48
Lessons Learned

The need to engage our private sector more in the MeTA process

MeTA has acted as a coordinating body for the pharmaceutical
sector players and stakeholders

The MeTA process has opened channels of communication
between different stakeholders and different countries

CSO as one of the stakeholder engagement with the MeTA
process complements the overall picture and highlights patients’
need

Reach a common understanding on concepts of pharmacoeconomics , transparency, evidence-based medicine (EBM) and
accountability
17/07/2015
Medicines Transparency Alliance
49
Lessons Learned Cont.

To engage parliament in the MeTA council process and to involve
the media more

We started to understand each of the other stakeholder
perspectives and identified that there were in fact common
priorities and one objective between us to work on together

The Data Disclosure survey was a useful exercise that improved
communication and sharing/disclosing of information which is a
core MeTA principle

We have learned the importance of data disclosure and sharing
information
17/07/2015
Medicines Transparency Alliance
MeTA
50
Thank you

Ibrahim Alabbadi

PharmacoEconomist

Email: [email protected]

Mobile number: +962-777160810

Skype:

Website: www.ju.edu.jo
17/07/2015
Medicines Transparency Alliance
51
Civil Society
Dr Abdel Fattah Al Kilani
MeTA Council Member
17/07/2015
Medicines Transparency Alliance
52
CSO Sector overview

A total of 240 societies are registered officially in the ministry
of social development, yet not all are active neither
represents patient groups

The history in working with the Civil Society Organizations in
Jordan started in March 2008 when (HAI) facilitated a
meeting/workshop for the CSO with the objective of bringing
civil society groups together to take a decision as a group to
form an independent alliance that will work effectively to
enhance its role in policy planning and presenting the
WHO/HAI survey results to them
17/07/2015
Medicines Transparency Alliance
MeTA
53
Summary Analysis at start of MeTA




Limited CSO role in influencing healthcare strategies and policies
in Jordan
Limited effectiveness and authority in solving patients’ problems
regarding availability and affordability of medicines
Major limitation on the CSO’s fundraising ability due to restriction
by the Ministry of Social Development on the number of
fundraising events (only two annually)
There is an absence of coordination or sharing of expertise and
experiences among the various CSOs
17/07/2015
Medicines Transparency Alliance
54
Summary Analysis at start of MeTA
Cont.
At the early stage of MeTA, the MeTA/ CSO committee has
identified the following areas to include in the CSO workplan:
Priority Area 1: Engaging Civil Society Organizations (CSOs) to
work together on promoting Transparency in the Medicines
Supply Chain and improve Access to Medicines
Priority Area 2: To continue to build capacity among CSOs to
analyze data and explore and recommend policy options around
medicines availability and affordability, promotion and prescribing
practices, RDU and the use of generics
Priority Area 3: Communication and Coordination
17/07/2015
Medicines Transparency Alliance
55
Major milestones

The very first activity was conducted to map and identify CSOs to
assess their ability and willingness to work together and to
engage them with the MeTA council, this activity has set the
baseline work for the CSOs in Jordan

Workshop on building capacity of CSOs in order to strengthen
their ability to monitor and increase accountability of all
stakeholders regarding medicines prices, availability, selection
.
and quality of medicines in the public and private sectors The
main objective of the workshop was to introduce CSOs to
medicines regulations and health polices

Participate in the Harvard Flagship course

Participate in the country exchange visit to the Philippines

Conduct a training on advocacy and communications in
improving access to essential medicines
17/07/2015
Medicines Transparency Alliance
56
Success

The MeTA Council has identified Building capacity in
pharmaceutical policies for CSOs as one of its three main
areas in the country workplan

The CSO committee has drafted a CSO workplan according
to the three major priorities in the overall national MeTA
workplan in Jordan, “Build capacity of (CSOs) to monitor and
increase accountability of all stakeholders concerning the
prices, availability, selection and quality of medicines in the
public and private sectors

The specific CSO workplan was approved and a MOU has
been signed

CSOs are engaged in the MeTA initiatives

A nucleus of CSO coalition started to form
17/07/2015
Medicines Transparency Alliance
MeTA
57
Success Cont.

The CSO level of engagement with the MeTA process is moving
forward gradually

At the start of the process there was limited activities and
meetings but since November 09 they became more engaged

The CSO representative and patient groups actively participated
in all MeTA Jordan activities ( MeTA launch, MeTA forum, many
workshops)

The voice of patient is becoming heard from policy makers in the
public sector/ example MS patient society

Patient group representatives has 2 seats in the MeTA council

A workshop on advocacy and communication was organized for
CSOs with emphasis on team building activity, communication
skills, persuasion & negotiation skills, advocacy, how to form a
Coalition and engagement with the Media
17/07/2015
Medicines Transparency Alliance
58
Challenges

Poor role of the CSOs in the decision making process

Few of the patient groups societies budget is partially
supported by pharmaceutical companies

CSOs are still not represented in medicines related
committees such as : the pricing committee, higher drug
committee / JFDA

Limited CSOs role in improving patient counseling

Encouraging new patient groups societies to join the
coalition is a challenge

Shortages of medicines availability in public health and high
prices of medicine in the private sector
17/07/2015
Medicines Transparency Alliance
MeTA
59
Challenges Cont.

Limited participation of CSO representatives in Data disclosure
survey tool

MOU has taken some time to be approved and signed,
accordingly funds were not available for CSO until a later stage

CSOs need a coordinator to follow up on the activities listed in
their work plan

Reach a common understanding on the role of the patients
focusing on the regulations ,distribution of medicines and rational
drug use
17/07/2015
Medicines Transparency Alliance
60
Lessons Learned

A budget for a CSO coordinator should have been listed in the
CSO workplan

CSO engagement with the MeTA process complements the
overall picture and highlights patients’ need

Capacity for CSOs to engage more effectively needs to be built

To engage parliament in the MeTA council process

There should be an organized structure for the CSO coalition and
the CSO already started working towards forming an organized
way on, also formed a three committees on their meeting on the
22 June 2010
17/07/2015
Medicines Transparency Alliance
61
Lessons Learned Cont.

More participation of CSO representatives in Data disclosure
survey tool should have been considered

To involve media more

The stakeholders started to understand each others perspectives
CSOs realized that this should have been happened earlier

The CSO engagement with the process complement the overall
picture and uncovers the patients’ needs
17/07/2015
Medicines Transparency Alliance
62
Examples of Interested Civil Society Organizations
Patient Groups
NGOs
Diabetes
Association
Jordan cancer
society
Jordan ass. For
hemophilia &
Thalasemia
Environmental
Protection Society
Jordan Association
for Consumer
Protection
cerebral palsy
foundation
Kidney patients
friends society
Jordan ass. For
diabetic and
cancer pt.
Jordanian society
for tonsumer
protection
Jordan medical
association
IBN-CINA FOR
CELEBRAL
palsy
Jordan Rose of
Hope Society for
arthritis pt.
Jordanian
psychiatric
rehabilitation
society
Jordan pharmacist
association
Garden and Home
Association
liver patients
friends society
Jordanian friends of
behcet's disease pt.
society
Jordan society
for phenyl-keton
urea
Jordan cultural
ass. For
development of
law and legal
capacities
multiple sclerosis
society
The Jordanian
friends of cystic
fibrosis association
Media
AL GHAD
newspaper- Jordan
Thank you

Dr Abdel Fattah Al Kilani

Consumer Protection Organization Representative

Email

Mobile number +962 799958059

Website
17/07/2015
[email protected]
www.meta.jo
Medicines Transparency Alliance
64